GlassScriptPhysician profile
Nathan Michael Vollbrecht
NPI 1932893591
$3,382.96
in general payments reported to CMS, 2019-2025
23 companies · $2,807 in 2025
The $2,807 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $411 · 2024: $164 · 2025: $2,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,381 · Education: $2.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,380.56 |
| Education | $2.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $479.99 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $417.72 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $380.35 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $340.88 | 2023-2025 | Caplyta |
| Corium, LLC | $324.98 | 2025 | Azstarys |
| Lundbeck LLC | $197.12 | 2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $177.80 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $158.57 | 2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $147.86 | 2023 | Jornay Pm |
| Alkermes, INC. | $110.11 | 2024-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $99.49 | 2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $87.47 | 2024-2025 | Ingrezza |
| Tris Pharma INC | $71.76 | 2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $54.64 | 2025 | Trintellix |
| Bausch Health US, LLC | $54.56 | 2025 | Aplenzin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $45.12 | 2025 | Relexxii |
| E.R. Squibb & Sons, L.L.C. | $44.91 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $42.85 | 2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $42.39 | 2025 | Austedo Xr |
| Almatica Pharma LLC | $41.84 | 2025 | Loreev Xr |
| Indivior INC. | $27.31 | 2024 | Perseris |
| Neos Therapeutics, LP | $17.68 | 2025 | Adzenys Xr-Odt |
| Harmony Biosciences LLC | $17.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Vollbrecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.